ADVERTISEMENT

KRAS-mutated colorectal cancer: adagrasib with or without cetuximab shows promise

Miriam Davis, PhD   |   Clinical Summary   |   11 January 2023
ADVERTISEMENT

Background

  • KRAS  is the most frequently mutated oncogene in human cancer, including colorectal cancer.
  • Adagrasib was recently approved by the US Food and Drug Administration for advanced non-small cell lung cancer.
  • Adagrasib is a highly targeted, orally acting inhibitor of the mutant KRAS G12C protein ( KRAS  G12C refers to a...

          

Topic Challenges

left
right